Dmitry Balyasny’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-384,364
| Closed | -$8.05M | – | 3414 |
|
|
2026
Q1 | $8.05M | Sell |
384,364
-135,690
| -26% | -$3.06M | 0.01% | 1135 |
|
|
2025
Q4 | $12M | Buy |
+520,054
| New | +$17.1M | 0.02% | 944 |
|
|
2025
Q3 | – | Sell |
-70,495
| Closed | -$2.11M | – | 3376 |
|
|
2025
Q2 | $2.56M | Sell |
70,495
-42,270
| -37% | -$1.52M | ﹤0.01% | 1605 |
|
|
2025
Q1 | $4.08M | Buy |
112,765
+2,865
| +3% | +$119K | 0.01% | 1352 |
|
|
2024
Q4 | $4.62M | Buy |
+109,900
| New | +$5.45M | 0.01% | 1322 |
|
|
2024
Q2 | – | Sell |
-28,743
| Closed | -$1.34M | – | 3005 |
|
|
2024
Q1 | $1.34M | Sell |
28,743
-54,190
| -65% | -$2.56M | ﹤0.01% | 1673 |
|
|
2023
Q4 | $3.97M | Buy |
+82,933
| New | +$3.22M | 0.01% | 1202 |
|
|
2023
Q1 | – | Sell |
-1,219
| Closed | -$56.5K | – | 3064 |
|
|
2022
Q4 | $56.5K | Buy |
+1,219
| New | +$47.9K | ﹤0.01% | 2334 |
|
|
2021
Q4 | – | Sell |
-3,553
| Closed | -$320K | – | 2532 |
|
|
2021
Q3 | $320K | Buy |
+3,553
| New | +$321K | ﹤0.01% | 1575 |
|
|
2021
Q2 | – | Sell |
-4,612
| Closed | -$525K | – | 2285 |
|
|
2021
Q1 | $525K | Sell |
4,612
-4,646
| -50% | -$632K | ﹤0.01% | 1391 |
|
|
2020
Q4 | $1.28M | Buy |
+9,258
| New | +$1.1M | 0.01% | 973 |
|
|
2019
Q4 | – | Sell |
-7,823
| Closed | -$335K | – | 1436 |
|
|
2019
Q3 | $335K | Buy |
+7,823
| New | +$425K | ﹤0.01% | 1004 |
|
|
2019
Q2 | – | Sell |
-12,034
| Closed | -$835K | – | 1688 |
|
|
2019
Q1 | $835K | Sell |
12,034
-2,614
| -18% | -$149K | 0.01% | 1070 |
|
|
2018
Q4 | $637K | Buy |
+14,648
| New | +$801K | ﹤0.01% | 1035 |
|
|
2018
Q1 | – | Sell |
-9,400
| Closed | -$436K | – | 2251 |
|
|
2017
Q4 | $436K | Buy |
+9,400
| New | +$461K | ﹤0.01% | 1598 |
|
|
2017
Q3 | – | Sell |
-7,700
| Closed | -$478K | – | 2059 |
|
|
2017
Q2 | $478K | Buy |
7,700
+2,600
| +51% | +$157K | ﹤0.01% | 1238 |
|
|
2017
Q1 | $346K | Buy |
5,100
+1,800
| +55% | +$137K | ﹤0.01% | 1371 |
|
|
2016
Q4 | $232K | Buy |
+3,300
| New | +$234K | ﹤0.01% | 1257 |
|
|
2016
Q1 | – | Sell |
-43,750
| Closed | -$4.91M | – | 1480 |
|
|
2015
Q4 | $4.91M | Buy |
43,750
+1,534
| +4% | +$153K | 0.03% | 502 |
|
|
2015
Q3 | $4.07M | Buy |
42,216
+12,216
| +41% | +$1.4M | 0.03% | 557 |
|
|
2015
Q2 | $3.07M | Buy |
+30,000
| New | +$2.33M | 0.02% | 687 |
|
Other funds holding RARE
RI
FCM
Dmitry Balyasny's RARE Position: Q2 2026 in Review
Dmitry Balyasny sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 384,364 shares — an estimated $8.05M sold.
Dmitry Balyasny first reported a position in RARE in Q2 2015 and held it in 21 quarters. The position peaked at $12M in Q4 2025. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Dmitry Balyasny reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
- Dmitry Balyasny sold 384,364 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $8.05M.
- Dmitry Balyasny first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 21 quarters.
- Dmitry Balyasny's Ultragenyx Pharmaceutical position peaked at $12M in Q4 2025.
- 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.